The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States.
The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States.
复制标题
DOI：
10.1080/10550887.2020.1811455
复制
发表时间：
2021-01
影响因子：
2.3
通讯作者：
Messiah SE
中科院分区：
文献类型：
--
作者：
Vidot DC;Islam JY;Marlene Camacho-Rivera;Harrell MB;Rao DR;Chavez JV;Lucas G Ochoa;Hlaing WM;Weiner M;Messiah SE
药用大麻的临床适应症包括慢性疾病;因此，使用者（MCU）因SARS-CoV-2感染（COVID-19）而导致的发病率和死亡率风险增加。该研究旨在提供关于大麻使用和自我报告的行为变化的数据，这些数据来自先前存在慢性疾病的MCU，以应对大流行。对过去一年内自我报告使用药用大麻的≥ 18岁成人进行了基于互联网的问卷调查。数据来自2020年3月21日至4月23日的受访者;回复率为83.3%。通过COVID-19大麻健康问卷（Vidot et al. 2020）评估了健康状况和大麻使用频率、途径和模式。参与者（N = 1202）主要为非西班牙裔白色（82.5%）和52.0%的男性（平均年龄47.2岁）。报告最多的是精神健康（76.7%）、疼痛（43.7%）、心脏代谢（32.9%）、呼吸系统（16.8%）和自身免疫（12.2%）疾病。自COVID-19被宣布为大流行以来，与没有精神健康状况的人相比，有精神健康状况的人报告药用大麻使用增加了91%（调整后的比值比：1.91，95% CI：1.38 - 2.65）。6.8%报告疑似COVID-19症状。百分之二（2.1%）的人接受了COVID-19检测，只有一个阳性检测结果。一些MCU（16%）改变了大麻给药途径，改用非吸烟形式。大多数MCU报告至少有一种预先存在的慢性健康状况。超过一半的人报告害怕COVID-19诊断并将病毒传染给其他人;但只有一些人从吸烟转向非吸烟形式的大麻。临床医生可能会考虑询问他们的病人，特别是那些有慢性健康状况的病人使用大麻的情况。
Clinical indications for medicinal cannabis include chronic conditions; thus users (MCUs) are at an increased risk of morbidity and mortality resulting from SARS-CoV-2 infection (COVID-19). The study aimed to provide data on cannabis use and self-reported behavioral changes among MCUs with preexisting chronic conditions in response to the pandemic. An internet-based questionnaire was administered to adults ≥18 who self-reported medicinal cannabis use within the past year. Data are from respondents between March 21 and April 23, 2020; response rate was 83.3%. Health conditions and cannabis frequency, route, and patterns of use were assessed via the COVID-19 Cannabis Health Questionnaire (Vidot et al. 2020). Participants (N = 1202) were predominantly non-Hispanic white (82.5%) and 52.0% male (mean age 47.2 years). Mental health (76.7%), pain (43.7%), cardiometabolic (32.9%), respiratory (16.8%), and autoimmune (12.2%) conditions were most reported. Those with mental health conditions reported increased medicinal cannabis use by 91% since COVID-19 was declared a pandemic compared to those with no mental health conditions (adjusted odds ratio: 1.91, 95% CI: 1.38–2.65). 6.8% reported suspected COVID-19 symptoms. Two percent (2.1%) have been tested for COVID-19 with only 1 positive test result. Some MCUs (16%) changed their route of cannabis administration, switching to nonsmoking forms. The majority of MCUs reported at least one preexisting chronic health condition. Over half report fear of COVID-19 diagnosis and giving the virus to someone else; yet only some switched from smoking to nonsmoking forms of cannabis. Clinicians may consider asking about cannabis use among their patients, particularly those with chronic health conditions.
登录
查看更多内容
影响因子：
4.5
作者：
Vetter, Stefan;Rossegger, Astrid;Endrass, Jerome
通讯作者：
Endrass, Jerome
影响因子：
2
作者：
Wagner, Karla D.;Brief, Deborah J.;Malow, Robert
通讯作者：
Malow, Robert
影响因子：
5.9
作者：
Kilpatrick, DG;Acierno, R;Schnurr, PP
通讯作者：
Schnurr, PP
影响因子：
6
作者：
Allen, Alicia M.;Jung, Alesia M.;Alexander, Adam C.;Allen, Sharon S.;Ward, Kenneth D.;al'Absi, Mustafa
通讯作者：
al'Absi, Mustafa
影响因子：
4.4
作者：
Glodosky, Nicholas C.;Cuttler, Carrie
通讯作者：
Cuttler, Carrie